Close
  Indian J Med Microbiol
 

Figure 3: Medication use in patients with AF. (a) Major medication before and after the platform establishment. (b) Anticoagulation rates with different CHA2DS2-VASc scores (Congestive Heart Failure, Hypertension, Age =75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65–74, Female) between two groups. Anticoagulation rates were rapidly increasing in patients with different CHA2DS2-VASc scores, while the numbers of other adjunct medicines are decreasing. AAA=Antiarrhythmic agent, ACEI=Angiotensin-converting enzyme inhibitor, ARB=Angiotensin receptor blocker. Groups 1 and 2: Before or after the establishment of comprehensive AF management platform

Figure 3: Medication use in patients with AF. (a) Major medication before and after the platform establishment. (b) Anticoagulation rates with different CHA<sup>2</sup>DS<sup>2</sup>-VASc scores (Congestive Heart Failure, Hypertension, Age =75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65–74, Female) between two groups. Anticoagulation rates were rapidly increasing in patients with different CHA2DS2-VASc scores, while the numbers of other adjunct medicines are decreasing. AAA=Antiarrhythmic agent, ACEI=Angiotensin-converting enzyme inhibitor, ARB=Angiotensin receptor blocker. Groups 1 and 2: Before or after the establishment of comprehensive AF management platform